AR081221A1 - Anticuerpos anti gdf8 humano - Google Patents
Anticuerpos anti gdf8 humanoInfo
- Publication number
- AR081221A1 AR081221A1 ARP110101772A ARP110101772A AR081221A1 AR 081221 A1 AR081221 A1 AR 081221A1 AR P110101772 A ARP110101772 A AR P110101772A AR P110101772 A ARP110101772 A AR P110101772A AR 081221 A1 AR081221 A1 AR 081221A1
- Authority
- AR
- Argentina
- Prior art keywords
- gdf8
- antibody
- tgfb1
- human
- fragment
- Prior art date
Links
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 title abstract 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 206010065687 Bone loss Diseases 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 102000001690 Factor VIII Human genes 0.000 abstract 1
- 108010054218 Factor VIII Proteins 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 208000010428 Muscle Weakness Diseases 0.000 abstract 1
- 206010028372 Muscular weakness Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 102000054677 human MSTN Human genes 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003907 kidney function Effects 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 208000001076 sarcopenia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Radiology & Medical Imaging (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona un anticuerpo humano o humanizado aislado o un fragmento del mismo que se une específicamente al factor de crecimiento y diferenciación 8 (GDF8) y bloquea la actividad de GDF8. El anticuerpo o el fragmento de anticuerpo es útil en un método terapéutico para el tratamiento de una afección o trastorno que mejora mediante la inhibición de GDF8, tal como la pérdida de tejido muscular, asociada a distrofia muscular, atrofia muscular, síndrome de debilitación muscular, sarcopenia o caquexia; metabolismo alterado o diabetes tipo 2 para mejorar la homeostasis de la glucosa, disminuir la masa de grasa, incrementar la sensibilidad a la insulina, mejorar la función renal y/o disminuir la acumulación de grasas; o una afección caracterizada por la pérdida ósea, por ejemplo, asociada a osteoporosis, osteopenia, osteoartritis y/o fracturas óseas. Dicho anticuerpo no se una a la construcción quimérica BDF8/TGFb1, que tiene los aminoácidos 48 - 72 de GDF8 humano maduro sustituidos por la secuencia de aminoácidos de TGFb1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34855910P | 2010-05-26 | 2010-05-26 | |
| US37288210P | 2010-08-12 | 2010-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR081221A1 true AR081221A1 (es) | 2012-07-04 |
Family
ID=44477626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110101772A AR081221A1 (es) | 2010-05-26 | 2011-05-24 | Anticuerpos anti gdf8 humano |
Country Status (42)
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102057826B1 (ko) | 2008-04-11 | 2019-12-20 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복 결합하는 항원 결합 분자 |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| NZ608206A (en) | 2010-08-16 | 2015-02-27 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| MX350355B (es) | 2011-11-14 | 2017-09-04 | Regeneron Pharma | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. |
| JO3820B1 (ar) * | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| TW201823460A (zh) | 2012-05-29 | 2018-07-01 | 美商再生元醫藥公司 | 生產細胞株增強子 |
| JP6774164B2 (ja) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | マウスＦｃγＲＩＩ特異的Ｆｃ抗体 |
| KR102854939B1 (ko) | 2012-08-24 | 2025-09-03 | 추가이 세이야쿠 가부시키가이샤 | ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체 |
| WO2014043344A1 (en) | 2012-09-13 | 2014-03-20 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to myostatin |
| AU2013334660B2 (en) | 2012-10-24 | 2018-08-09 | Celgene Corporation | Methods for treating anemia |
| KR102218494B1 (ko) | 2013-03-15 | 2021-02-19 | 인트린식 라이프사이언시스, 엘엘씨 | 항-헵시딘 항체 및 그의 용도 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| HRP20251426T1 (hr) | 2013-05-06 | 2026-01-02 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| US10323088B2 (en) | 2014-09-22 | 2019-06-18 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| HK1243940A1 (zh) | 2014-11-06 | 2018-07-27 | Scholar Rock, Inc. | 抗原肌肉生长抑制素/潜在肌肉生长抑制素的抗体及其用途 |
| WO2016085860A1 (en) * | 2014-11-24 | 2016-06-02 | Somalogic, Inc. | Nucleic acid compounds for binding growth differentiation factor 11 |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| MX2017008978A (es) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos. |
| WO2016128523A1 (en) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
| CA2982810A1 (en) * | 2015-04-15 | 2016-10-20 | Regeneron Pharmaceuticals, Inc. | Methods of increasing strength and functionality with gdf8 inhibitors |
| TW202440904A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（二） |
| BR112018004981A2 (pt) | 2015-09-15 | 2018-10-09 | Scholar Rock, Inc. | anticorpos anti-pró-miostatina/miostatina latente e usos destes. |
| KR20230027321A (ko) | 2015-12-18 | 2023-02-27 | 추가이 세이야쿠 가부시키가이샤 | 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법 |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| KR20180094110A (ko) | 2016-01-08 | 2018-08-22 | 스칼러 락, 인크. | 항-프로/잠재성 미오스타틴 항체 및 그의 사용 방법 |
| KR20230169484A (ko) | 2016-06-13 | 2023-12-15 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| JP6196411B1 (ja) | 2016-06-17 | 2017-09-13 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| CN116251182A (zh) | 2016-08-05 | 2023-06-13 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| CN106770517A (zh) * | 2016-12-16 | 2017-05-31 | 青岛科技大学 | 一种检测力竭运动后小鼠骨骼肌肌肉生长抑制素含量的方法 |
| US11352417B2 (en) | 2016-12-22 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| AU2018205270B2 (en) | 2017-01-06 | 2022-08-11 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| KR20250041082A (ko) | 2017-07-06 | 2025-03-25 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
| EP3727629A1 (en) | 2017-12-22 | 2020-10-28 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| EP3731865A1 (en) * | 2017-12-29 | 2020-11-04 | F. Hoffmann-La Roche AG | Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody |
| JP7349998B2 (ja) | 2018-01-31 | 2023-09-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | サイズバリアントおよび電荷バリアントである薬物製品不純物を特徴解析するためのシステムおよび方法 |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| JP2021514609A (ja) | 2018-02-28 | 2021-06-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ウイルス混入物質を同定するためのシステムおよび方法 |
| KR20200128125A (ko) | 2018-03-01 | 2020-11-11 | 리제너론 파아마슈티컬스, 인크. | 신체 조성을 변경하기 위한 방법 |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| MY202358A (en) | 2018-03-19 | 2024-04-24 | Regeneron Pharma | Microchip capillary electrophoresis assays and reagents |
| SI3773713T1 (sl) | 2018-04-06 | 2025-08-29 | Regeneron Pharmaceuticals, Inc. | Protitelo, agonist leptinskega receptorja, za uporabo pri povečanju kostne mase pri osebi, ki trpi zaradi presnovne disfunkcije ali hipoleptinemije |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| EP3774841A1 (en) | 2018-08-27 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Use of raman spectroscopy in downstream purification |
| CA3100038A1 (en) | 2018-08-30 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
| CN113195532B (zh) * | 2018-12-18 | 2025-04-11 | 瑞泽恩制药公司 | 使用针对瘦素受体、gdf8和活化素a的拮抗剂增加体重和瘦肌肉质量的组合物和方法 |
| BR112021009543A2 (pt) | 2019-01-16 | 2021-08-17 | Regeneron Pharmaceuticals, Inc. | métodos para identificar tióis livres em um medicamento de proteína, de identificação de heterogeneidade de dissulfeto em um medicamento de proteína e para selecionar um medicamento de proteína, e, composição farmacêutica |
| SG11202110911RA (en) | 2019-05-13 | 2021-10-28 | Regeneron Pharma | Improved competitive ligand binding assays |
| PH12022550630A1 (en) | 2019-09-24 | 2023-03-27 | Regeneron Pharma | Systems and methods for chromatography use and regeneration |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| CA3155759A1 (en) * | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| WO2021142269A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
| WO2021142331A1 (en) * | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
| WO2021150558A1 (en) | 2020-01-21 | 2021-07-29 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| BR112023003273A2 (pt) | 2020-08-31 | 2023-05-02 | Regeneron Pharma | Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina |
| US12239687B2 (en) | 2020-11-25 | 2025-03-04 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous membrane emulsification |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| AU2022209730A1 (en) | 2021-01-20 | 2023-07-13 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| BR112023017442A2 (pt) | 2021-03-03 | 2023-09-26 | Regeneron Pharma | Métodos para identificar regiões em uma proteína e para modificar a viscosidade de uma droga proteica, e, droga proteica |
| KR20230162932A (ko) | 2021-03-26 | 2023-11-29 | 리제너론 파아마슈티컬스, 인크. | 혼합 프로토콜 개발을 위한 방법 및 시스템 |
| EP4348234A1 (en) | 2021-06-01 | 2024-04-10 | Regeneron Pharmaceuticals, Inc. | Micropchip capillary electrophoresis assays and reagents |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| EP4405390A1 (en) | 2021-09-20 | 2024-07-31 | Regeneron Pharmaceuticals, Inc. | Methods of controlling antibody heterogeneity |
| WO2023059803A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | Ph meter calibration and correction |
| CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
| IL312372A (en) | 2021-10-26 | 2024-06-01 | Regeneron Pharma | Systems and methods for producing laboratory water and dispersing laboratory water at different temperatures |
| KR20240164561A (ko) | 2022-03-18 | 2024-11-19 | 리제너론 파아마슈티컬스, 인크. | 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템 |
| US20240199728A1 (en) | 2022-09-21 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods of treating obesity, diabetes, and liver dysfunction |
| JP2026500269A (ja) | 2022-12-16 | 2026-01-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーカラムの完全性を評価するための方法及びシステム |
| CN120677175A (zh) | 2022-12-22 | 2025-09-19 | 供石公司 | 肌生成抑制蛋白活化的选择性和强效抑制剂 |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| WO2024163708A1 (en) | 2023-02-01 | 2024-08-08 | Regeneron Pharmaceuticals, Inc. | Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| WO2025064403A2 (en) | 2023-09-18 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| US20260000758A1 (en) | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| DE69432815T2 (de) | 1993-03-19 | 2003-12-11 | The Johns Hopkins University School Of Medicine, Baltimore | Wachstumsfaktor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2331410C (en) | 1998-05-06 | 2009-07-14 | Metamorphix, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
| EA005248B1 (ru) | 1999-07-20 | 2004-12-30 | Фармекса А/С | Способ отрицательной регуляции активности gdf-8 |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7261893B2 (en) | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| RS52815B (sr) * | 2002-12-20 | 2013-10-31 | Amgen Inc. | Vezivna sredstva koja inhibiraju miostatin |
| KR20060026860A (ko) | 2003-06-02 | 2006-03-24 | 와이어쓰 | 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도 |
| MXPA06007514A (es) | 2003-12-31 | 2006-08-31 | Schering Plough Ltd | Vacuna para mejorar el crecimiento a base de epitopes neutralizantes. |
| US7456149B2 (en) | 2004-03-02 | 2008-11-25 | Acceleron Pharma, Inc. | ALK7 and myostatin inhibitors and uses thereof |
| EP1733041B1 (en) | 2004-03-23 | 2012-05-09 | Eli Lilly & Company | Anti-myostatin antibodies |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| WO2006020884A2 (en) | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| CA2605723A1 (en) * | 2005-04-25 | 2006-11-02 | Pfizer Inc. | Antibodies to myostatin |
| EP3327033A1 (en) | 2005-08-19 | 2018-05-30 | Wyeth LLC | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| CN101277976B (zh) * | 2005-10-06 | 2012-04-11 | 伊莱利利公司 | 抗肌抑制素抗体 |
| UA92504C2 (en) | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
| CA2856436A1 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc. | Uses of myostatin antagonists |
| US7699146B1 (en) | 2006-04-02 | 2010-04-20 | Fox Factory, Inc. | Suspension damper having inertia valve and user adjustable pressure-relief |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| EP2054434B1 (en) * | 2006-08-03 | 2017-03-15 | Myostin Therapeutics Pty Ltd | Myostatin antagonists |
| WO2008030706A2 (en) * | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| CN100586476C (zh) * | 2006-10-13 | 2010-02-03 | 中国人民解放军第四军医大学 | 一种Myostatin特异性抗体的治疗性疫苗及其制备方法 |
| TWI454479B (zh) | 2007-03-06 | 2014-10-01 | Amgen Inc | 變異之活動素受體多肽及其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| AR069165A1 (es) | 2007-11-05 | 2010-01-06 | Novartis Ag | Derivados de 4-bencilamino-1-carboxacilpiperidina como inhibidores de cetp utiles para el tratamiento de hiperlipidemia |
| HUE063136T2 (hu) | 2008-08-14 | 2023-12-28 | Acceleron Pharma Inc | GDF-Csapdák |
| AR074777A1 (es) | 2008-12-19 | 2011-02-09 | Glaxo Group Ltd | Proteinas de union a antigeno |
| EA027071B1 (ru) | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| KR102010827B1 (ko) | 2009-06-26 | 2019-08-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| JO3340B1 (ar) * | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| MX350355B (es) | 2011-11-14 | 2017-09-04 | Regeneron Pharma | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
-
2011
- 2011-05-17 JO JOP/2011/0164A patent/JO3340B1/ar active
- 2011-05-24 AR ARP110101772A patent/AR081221A1/es active IP Right Grant
- 2011-05-25 HU HUE11726005A patent/HUE037140T2/hu unknown
- 2011-05-25 EP EP11726005.9A patent/EP2576618B1/en active Active
- 2011-05-25 HR HRP20171499TT patent/HRP20171499T1/hr unknown
- 2011-05-25 PH PH1/2012/502187A patent/PH12012502187B1/en unknown
- 2011-05-25 TW TW100118221A patent/TWI602917B/zh active
- 2011-05-25 UY UY0001033407A patent/UY33407A/es unknown
- 2011-05-25 LT LTEP11726005.9T patent/LT2576618T/lt unknown
- 2011-05-25 RU RU2012156938/10A patent/RU2567805C2/ru active
- 2011-05-25 WO PCT/US2011/037837 patent/WO2011150008A1/en not_active Ceased
- 2011-05-25 RS RS20170931A patent/RS56368B1/sr unknown
- 2011-05-25 PL PL11726005T patent/PL2576618T3/pl unknown
- 2011-05-25 DK DK11726005.9T patent/DK2576618T3/en active
- 2011-05-25 ES ES11726005.9T patent/ES2647389T3/es active Active
- 2011-05-25 PE PE2012002209A patent/PE20130226A1/es active IP Right Grant
- 2011-05-25 MY MYPI2012004862A patent/MY157109A/en unknown
- 2011-05-25 US US13/115,170 patent/US8840894B2/en active Active
- 2011-05-25 TW TW105109351A patent/TW201701903A/zh unknown
- 2011-05-25 RU RU2015143242A patent/RU2710156C2/ru active
- 2011-05-25 SI SI201131297T patent/SI2576618T1/sl unknown
- 2011-05-25 JP JP2013512186A patent/JP5896993B2/ja active Active
- 2011-05-25 AU AU2011258342A patent/AU2011258342B2/en active Active
- 2011-05-25 CA CA2800581A patent/CA2800581C/en active Active
- 2011-05-25 NZ NZ603529A patent/NZ603529A/en unknown
- 2011-05-25 MX MX2012013369A patent/MX2012013369A/es active IP Right Grant
- 2011-05-25 PT PT117260059T patent/PT2576618T/pt unknown
- 2011-05-25 KR KR1020127033587A patent/KR101859911B1/ko active Active
- 2011-05-25 SG SG10201504092TA patent/SG10201504092TA/en unknown
- 2011-05-25 SM SM20170463T patent/SMT201700463T1/it unknown
- 2011-05-25 CN CN201180025908.2A patent/CN102933602B/zh active Active
- 2011-05-25 SG SG2012081964A patent/SG185455A1/en unknown
- 2011-05-25 BR BR112012029986-7A patent/BR112012029986B1/pt active IP Right Grant
- 2011-05-25 NO NO11726005A patent/NO2576618T3/no unknown
- 2011-05-25 MX MX2015005551A patent/MX357145B/es unknown
-
2012
- 2012-11-12 IL IL223003A patent/IL223003A/en active IP Right Grant
- 2012-11-13 ZA ZA2012/08525A patent/ZA201208525B/en unknown
- 2012-11-13 CR CR20120577A patent/CR20120577A/es unknown
- 2012-11-14 NI NI201200171A patent/NI201200171A/es unknown
- 2012-11-20 DO DO2012000295A patent/DOP2012000295A/es unknown
- 2012-11-23 GT GT201200318A patent/GT201200318A/es unknown
- 2012-11-23 TN TNP2012000555A patent/TN2012000555A1/en unknown
- 2012-11-23 CL CL2012003283A patent/CL2012003283A1/es unknown
- 2012-11-26 EC ECSP12012309 patent/ECSP12012309A/es unknown
- 2012-12-26 CO CO12233131A patent/CO6620013A2/es unknown
-
2014
- 2014-08-18 US US14/462,085 patent/US9260515B2/en active Active
-
2015
- 2015-12-18 US US14/974,147 patent/US9890212B2/en active Active
-
2017
- 2017-10-11 CY CY20171101065T patent/CY1119445T1/el unknown
-
2018
- 2018-01-02 US US15/860,200 patent/US20190023777A1/en not_active Abandoned
-
2022
- 2022-10-11 US US18/045,588 patent/US20240067712A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR081221A1 (es) | Anticuerpos anti gdf8 humano | |
| EA201301107A1 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| EP2415749A4 (en) | NOVEL SALVIANOLIC ACID COMPOUND L, PROCESS FOR THE PREPARATION AND USE | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| EA201000559A1 (ru) | Композиции и способы применения антител к склеростину | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| MX357193B (es) | Moleculas de union anti-alfa sinucleina. | |
| WO2009017679A3 (en) | Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders | |
| MX2015008079A (es) | Agonista duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201991345A1 (ru) | Новые соединения в качестве пептидных тройных агонистов рецепторов glp1/глюкагона/gip | |
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| EA201490677A1 (ru) | Связывающие антиген cd27l белки | |
| CR10736A (es) | Composiciones y metodos relacionados con los anticuerpos del receptor del glucagon | |
| PE20130815A1 (es) | Una composicion de combinacion farmaceutica y metodos para tratar la diabetes y los trastornos metabolicos | |
| UA102775C2 (uk) | Спосіб лікування болю із застосуванням анти-ngf антитіла | |
| EA201690520A1 (ru) | Способ получения замещенных 5-фтор-1h-пиразолопиридинов | |
| EA201100778A1 (ru) | Гетероциклические замещенные соединения в качестве ингибиторов hif | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| EA201892184A1 (ru) | Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора | |
| WO2010080756A3 (en) | Harmine derivatives for reducing body weight | |
| AR077972A1 (es) | Anticuerpos contra cdcp1 destinados al tratamiento del cancer | |
| WO2013078376A3 (en) | Isoxazole treatments for diabetes | |
| EA201690490A1 (ru) | Миметики инсулиноподобного фактора роста для применения в терапии | |
| WO2012094511A3 (en) | Compositions and methods for the treatment of orthopedic disease or injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |